XML 54 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Development, Commercialization and Supply Agreement - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2024
Oct. 31, 2023
Jun. 30, 2023
Feb. 28, 2023
Jan. 31, 2023
Feb. 29, 2020
Jan. 31, 2020
Sep. 30, 2018
Sep. 30, 2017
Mar. 31, 2016
Feb. 28, 2015
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2018
Dec. 31, 2022
License And Collaboration Agreements [Line Items]                                
Revenue recognized related to upfront and milestone payments                         $ 445,000      
Licenses revenue                       $ 56,519,000 85,975,000      
Deferred revenue                       4,449,000 14,901,000 $ 4,850,000   $ 15,346,000
Product Revenue, Net                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                       55,156,000 84,654,000      
Out-licenses                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                         300,000      
Mochida Pharmaceutical Co., Ltd. | In-licenses                                
License And Collaboration Agreements [Line Items]                                
Milestones payment $ 1,000,000       $ 1,000,000                      
Mochida Pharmaceutical Co., Ltd. | In-licenses | Research and Development Expense                                
License And Collaboration Agreements [Line Items]                                
Up-front payment                             $ 2,700,000  
Edding | Out-licenses                                
License And Collaboration Agreements [Line Items]                                
Non-refundable up-front received                     $ 15,000,000          
Amounts to be received upon achievement of the regulatory milestone events                       25,000,000        
Milestone payments received                       9,000,000        
Sales-based milestone event payment                       120,000,000        
Revenue recognized related to upfront and milestone payments                       400,000 300,000      
Deferred revenue                       4,000,000   4,400,000    
Edding | Out-licenses | Licensing Revenue                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                       21,000,000   20,600,000    
Edding | Out-licenses | Product Revenue, Net                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                       3,400,000        
Edding | Out-licenses | Maximum                                
License And Collaboration Agreements [Line Items]                                
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                       145,000,000        
Amounts to be received upon achievement of the regulatory milestone events                       15,000,000        
Sales-based milestone event payment                       50,000,000        
Edding | Out-licenses | Minimum                                
License And Collaboration Agreements [Line Items]                                
Amounts to be received upon achievement of the regulatory milestone events                       2,000,000        
Sales-based milestone event payment                       5,000,000        
Edding | Out-licenses | Clinical Trial Application                                
License And Collaboration Agreements [Line Items]                                
Non-refundable milestone payment received                   $ 1,000,000            
Edding | Out-licenses | Achievement of REDUCE-IT Trial                                
License And Collaboration Agreements [Line Items]                                
Non-refundable milestone payment received   $ 3,000,000                            
Edding | Out-licenses | Marine | VASCEPA                                
License And Collaboration Agreements [Line Items]                                
Non-refundable milestone payment received     $ 5,000,000                 $ 5,000,000        
Edding | Out-licenses | Marine | Maximum                                
License And Collaboration Agreements [Line Items]                                
Revenue recognition period of non-refundable up-front payment                       3 years        
Edding | Out-licenses | Marine | Minimum                                
License And Collaboration Agreements [Line Items]                                
Revenue recognition period of non-refundable up-front payment                       11 years        
Biologix FZCo                                
License And Collaboration Agreements [Line Items]                                
Revenue recognition period of non-refundable up-front payment                       8 years        
Biologix FZCo | Out-licenses                                
License And Collaboration Agreements [Line Items]                                
Revenue recognition period of non-refundable up-front payment                   10 years            
HLS | Out-licenses                                
License And Collaboration Agreements [Line Items]                                
Non-refundable up-front received                 $ 5,000,000              
Non-refundable milestone payment received           $ 2,500,000 $ 3,800,000 $ 2,500,000                
Revenue recognized related to upfront and milestone payments                       $ 100,000        
Non-refundable up-front received period                 6 months              
Non-refundable milestone payment received                 $ 3,800,000              
HLS | Out-licenses | Health Canada                                
License And Collaboration Agreements [Line Items]                                
Non-refundable milestone payment received                 2,500,000              
HLS | Out-licenses | Licensing Revenue                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                       13,700,000   $ 13,700,000    
HLS | Out-licenses | Product Revenue, Net                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                       $ 1,900,000 1,600,000      
HLS | Out-licenses | Maximum                                
License And Collaboration Agreements [Line Items]                                
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                 50,000,000              
HLS | Out-licenses | Achievement of REDUCE-IT Trial                                
License And Collaboration Agreements [Line Items]                                
Non-refundable milestone payment received                 $ 2,500,000              
CSL Seqirus | Out-licenses                                
License And Collaboration Agreements [Line Items]                                
Non-refundable up-front received       $ 500,000                        
Licenses revenue                         $ 500,000      
Upfront payment receivable       500,000                        
Event-related milestone payments receivable       8,000,000                        
Additional product-related milestone payments receivable       $ 4,000,000